Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.70
+0.83 (3.21%)
Jan 21, 2026, 4:00 PM EST - Market closed
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 342 employees as of December 31, 2024. The number of employees increased by 46 or 15.54% compared to the previous year.
Employees
342
Change (1Y)
46
Growth (1Y)
15.54%
Revenue / Employee
$929,617
Profits / Employee
-$129,602
Market Cap
3.27B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Dec 31, 2020 | 54 | 25 | 86.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Beam Therapeutics | 483 |
| Xenon Pharmaceuticals | 327 |
| Tarsus Pharmaceuticals | 323 |
| Catalyst Pharmaceuticals | 181 |
| Alumis | 170 |
| Liquidia | 170 |
| Viridian Therapeutics | 143 |
| IDEAYA Biosciences | 131 |
ARQT News
- 23 hours ago - Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions - GlobeNewsWire
- 9 days ago - Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones - GlobeNewsWire
- 6 weeks ago - Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - GlobeNewsWire
- 6 weeks ago - Arcutis Biotherapeutics: The Earnings Inflection Has Arrived - Seeking Alpha
- 2 months ago - FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 - GlobeNewsWire
- 2 months ago - PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 2 months ago - Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - GlobeNewsWire
- 2 months ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire